Key result
Early warfarin initiation (2.7 vs 4.3 days, p=0.03) and faster time to therapeutic INR (1.3 vs 2.6 days, p=0.04) predicted INRs ≥ 5 in cardiothoracic surgery patients.
Why the study?
Half of the inpatient warfarin cases meeting the Vizient INR >= 5 threshold occurred in cardiothoracic surgery patients, prompting investigation into patient-specific risk factors and dosing approaches.
Does earlier warfarin initiation increase the risk of INR ≥ 5 in cardiothoracic surgery patients?
Does earlier warfarin initiation increase the risk of INR ≥ 5 in cardiothoracic surgery patients?
Traditional risk factors and starting dose did not predict supratherapeutic INR in post-cardiothoracic surgery patients, suggesting that a standardized dosing protocol may be safe and appropriate.
May warrant delaying warfarin initiation after cardiothoracic surgery; challenges traditional risk factors and supports standardized protocols.
Introduction: Warfarin is a commonly used oral anticoagulant with a narrow therapeutic index and risk for supratherapeutic anticoagulation. In October 2017, Vizient implemented a lab-based metric tracking the percentage of adult inpatients receiving warfarin who develop an INR ≥ 5. Exclusions include therapy < 3 days, admission INR >3.5, and argatroban use. Though not tied to bleeding outcomes, the metric serves as a surrogate for anticoagulation safety. In FY24, 7% (24/343) of UK HealthCare inpatients on warfarin met the INR ≥ 5 threshold, with 50% of cases in cardiothoracic (CT) surgery patients—prompting investigation into patient-specific risk factors and dosing approaches. Methods: This retrospective cohort quality improvement study identified CT surgery patients treated with warfarin in FY24 using EPIC SlicerDicer. Patients were stratified by INR outcome (≥5 vs. < 5). Endpoints included warfarin indication, valve type/location, redo sternotomy, cardiopulmonary bypass time, time to warfarin initiation, time to therapeutic INR, initial dose, INR trends, and hospital length of stay (LOS). Results: Among 59 CT surgery patients, 11 (18.6%) developed INR ≥ 5. These patients received warfarin earlier (mean 2.7 vs. 4.3 days, p=0.03) and reached therapeutic INR faster (mean 1.3 vs. 2.6 days, p=0.04). Time from INR > 2 to discharge was longer in the INR ≥ 5 group (median 13 vs. 6 days, p=0.02). Starting dose did not predict INR ≥ 5 (p=0.41), and supratherapeutic INR occurred even with lower doses (2–2.5 mg). Initial dose also did not impact LOS or time to therapeutic INR (p>0.05). Valve type, bypass time, and number of doses were not significantly associated with INR ≥ 5 (all p>0.3), though mitral valve patients with INR ≥ 5 had the longest LOS (47 days). Conclusions: Traditional risk factors for warfarin sensitivity—such as valve location, bypass time, and starting dose—did not predict INR ≥ 5. These findings suggest a standardized CT surgery-specific warfarin dosing protocol may be suitable across the broader post-op population, potentially improving anticoagulation safety and Vizient performance metrics.
No takes yet. Share an insight, caveat, or question.
Pandya et al. (2026) studied this question. Early warfarin initiation (2.7 vs 4.3 days, p=0.03) and faster time to therapeutic INR (1.3 vs 2.6 days, p=0.04) predicted INRs ≥ 5 in cardiothoracic surgery patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: